Payment overview · 2025
General Payments
$706.43
28 reported records · 14 companies
Healthcare provider profile · identity verified
Ravi Passi, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ROCKVILLE, MD · NPI 1114921665
Verified facts
What the public records show
CMS Open Payments records show Ravi Passi, MD received $706.43 in general payments during 2025 across 28 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 25.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 282 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $180.85 | 25.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $95.03 | 13.4% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $59.44 | 8.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.98 | 8.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.27 | 8.1% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $48.23 | 6.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $41.78 | 5.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $34.44 | 4.9% | 1 | 2025 |
| Cumberland Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.14 | 4.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.45 | 3.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.43 | 3.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.68 | 2.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.45 | 2.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.26 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $706.43 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $229.08 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $59.97 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $59.44 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $58.98 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $43.53 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $41.78 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $34.44 | 1 | 2025 |
Source payment records
|
|||||
| KRISTALOSE Normalized: kristalose |
Drug | Cumberland Pharmaceuticals, Inc. | $32.14 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.45 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.74 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 112 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
112 | 22 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
282 | 38 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
112 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 769 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 638 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 468 | 101 |
| Lisinopril | Lisinopril | 437 | 90 |
| Gabapentin | Gabapentin | 419 | 73 |
| Metformin Hcl | Metformin Hcl | 320 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 292 | 56 |
| Eliquis | Apixaban | 282 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 272 | 61 |
| Furosemide | Furosemide | 258 | 56 |
| Losartan Potassium | Losartan Potassium | 248 | 77 |
| Mirtazapine | Mirtazapine | 246 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 234 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 226 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 52 |
| Simvastatin | Simvastatin | 207 | 48 |
| Carvedilol | Carvedilol | 200 | 40 |
| Trazodone Hcl | Trazodone Hcl | 183 | 30 |
| Levetiracetam | Levetiracetam | 181 | 22 |
| Sertraline Hcl | Sertraline Hcl | 176 | 32 |
| Omeprazole | Omeprazole | 175 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 165 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 155 | 26 |
| Divalproex Sodium | Divalproex Sodium | 151 | 20 |
| Risperidone | Risperidone | 145 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 139 | 37 |
| Donepezil Hcl | Donepezil Hcl | 134 | 23 |
| Olanzapine | Olanzapine | 125 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 20 |
| Jardiance | Empagliflozin | 112 | 22 |
| Atenolol | Atenolol | 110 | 28 |
| Buspirone Hcl | Buspirone Hcl | 107 | 12 |
| Famotidine | Famotidine | 105 | 26 |
| Xarelto | Rivaroxaban | 99 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 98 | 26 |
| Potassium Chloride | Potassium Chloride | 97 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 27 |
| Finasteride | Finasteride | 89 | 17 |
| Memantine Hcl | Memantine Hcl | 81 | 17 |
| Januvia | Sitagliptin Phosphate | 80 | 16 |
| Baclofen | Baclofen | 79 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 65 | 24 |
| Glimepiride | Glimepiride | 61 | 15 |
| Clonidine Hcl | Clonidine Hcl | 60 | 16 |
| Nifedipine Er | Nifedipine | 58 | 11 |
| Glipizide | Glipizide | 57 | 13 |
| Montelukast Sodium | Montelukast Sodium | 55 | suppressed |
| Glipizide Er | Glipizide | 52 | 13 |
| Warfarin Sodium | Warfarin Sodium | 52 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 20 |
| Ezetimibe | Ezetimibe | 49 | 13 |
| Sucralfate | Sucralfate | 49 | suppressed |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 45 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | suppressed |
| Trulicity | Dulaglutide | 45 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 13 |
| Allopurinol | Allopurinol | 43 | 13 |
| Latanoprost | Latanoprost | 43 | suppressed |
| Entresto | Sacubitril/Valsartan | 42 | suppressed |
| Spironolactone | Spironolactone | 42 | suppressed |
| Meloxicam | Meloxicam | 41 | suppressed |
| Prednisone | Prednisone | 40 | 12 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 11 |
| Carbamazepine | Carbamazepine | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 11 |
| Lorazepam | Lorazepam | 35 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Clozapine | Clozapine | 33 | suppressed |
| Procrit | Epoetin Alfa | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Colchicine | Colchicine | 29 | suppressed |
| Gemtesa | Vibegron | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 20 |
| Tramadol Hcl | Tramadol Hcl | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Calcitriol | Calcitriol | 27 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Humalog | Insulin Lispro | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 27 | suppressed |
| Methotrexate | Methotrexate Sodium | 27 | suppressed |
| Scopolamine | Scopolamine | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 18 |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Clonidine | Clonidine | 22 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 14 |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Haloperidol | Haloperidol | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Nystatin | Nystatin | 17 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Levetiracetam Er | Levetiracetam | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | 13 |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Desloratadine | Desloratadine | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Ramelteon | Ramelteon | 14 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 13 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Tivicay | Dolutegravir Sodium | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Exelon | Rivastigmine | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Mesalamine Dr | Mesalamine | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $706.43 · 28 records | Otsuka America Pharmaceutical, Inc. | AREXVY, CAPLYTA, CAPVAXIVE, COBENFY, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, KISUNLA, KRISTALOSE, OTEZLA, REPATHA, REXULTI, SHINGRIX, TRELEGY ELLIPTA, Veozah, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error